Antheia, a pharmaceutical ingredient manufacturer transforming essential medicine supply chains, announced it has raised $56 million in Series C financing. The Series C funding round was led by Global Health Investment Corporation (GHIC), a U.S.-based investment firm with an established history of supporting innovation in global health and health security and EDBI, operating under SG Growth Capital – the investment platform of the Singapore Economic Development Board (EDB) and Enterprise Singapore. And new investors in this round include ATHOS KG and Federov, with participation from existing investors such as Viking Global Investors, Sherpalo Ventures, S-Cubed Capital, In-Q-Tel (IQT), and Civilization Ventures.
This news comes on the heels of several major milestones, including Antheia’s first commercial delivery of thebaine – the key ingredient used for producing Narcan – and two U.S. government project agreements valued up to a combined $23 million to onshore pharmaceutical supply chains. And Antheia’s strong commercial momentum and the broader industry response underscore the company’s vital role in modernizing global pharmaceutical supply chains and realizing biomanufacturing’s potential to solve the world’s most pressing problems.
How the funding will be used: The new funding will be used to expand commercialization of Antheia’s first product thebaine, and launch additional products from the company’s pipeline of 70+ biosynthetic pharmaceutical ingredients, which spans seven therapeutic areas and prioritizes essential medicines in or at risk of shortage. The funding will enable Antheia to unlock its U.S. manufacturing operations, meeting domestic demand, and initiate new strategic innovation programs in Singapore, while expanding into the broader Asia region.
Problem being addressed: Drug shortages remain a persistent major problem plaguing nations worldwide and are exacerbated by supply chain disruptions, climate crises, and shifting geopolitics. And Antheia’s platform is ushering in the next era of efficient, agile, and distributed pharmaceutical manufacturing that can be implemented when and where needed to meet the demands of 21st century healthcare systems.
KEY QUOTES:
“Our industry-first biosynthetic product offerings are disrupting the market by addressing major supply chain issues and are quickly cementing Antheia’s position as a leading industry innovator. In collaboration with our investors, customers, and manufacturing partners, we are enabling widespread access to critical medicines with our world-leading biosynthesis technology. We are immensely grateful to these partners that share our vision for the next generation of pharma, and we look forward to achieving more industry-first milestones with today’s financing.”
Dr. Christina Smolke, CEO and co-founder of Antheia
“Global pharmaceutical supply chains are complex and increasingly vulnerable to critical drug shortages – an urgent health security challenge. Antheia’s biosynthesis platform offers a transformative and elegant solution, enabling more efficient, scalable, and reliable production of KSMs and APIs. We are excited to support Antheia’s next phase of growth and to partner in building a more resilient future for global biomanufacturing.”
Joseph Lee, Principal at GHIC
“Antheia’s pioneering biosynthesis platform transforms essential medicine supply chains by addressing critical bottlenecks. As Singapore strengthens its position as Asia’s biotech hub, EDBI is proud to partner with Antheia to advance bio-based innovation. We see significant opportunities for Antheia to expand its biomanufacturing capabilities and applications through collaborations with Singapore’s vibrant scientific ecosystem – including A*STAR, Singapore’s lead public sector R&D agency – creating valuable synergies for future growth across Asia.”
Paul Ng, Chief Executive Officer of EDBI
